A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors
The study is being conducted to evaluate the efficacy, and safety of SHR-1901 in subjects with advanced malignant tumors.To explore the reasonable dosage of SHR-1901.
Advanced Malignant Tumors
DRUG: SHR-1901
Safety endpoints: Number of subjects with adverse events and the severity of adverse events, every 4 weeks after treatment initiation（through study completion，average 5 months)|DLT, during the first 28-day cycle of SHR-1901 treatment|MTD, 4 weeks after treatment initiation|RP2D, 4 weeks after treatment initiation
The study is being conducted to evaluate the efficacy, and safety of SHR-1901 in subjects with advanced malignant tumors.To explore the reasonable dosage of SHR-1901.